✦ LIBER ✦

Disease gravity and urgency of need as guidelines for liver allocation

✍ Scribed by Bijan Eghtesad; Oscar Bronsther; William Irish; Adrian Casavilla; Kareem Abu-Elmagd; David Van Thiel; Andreas Tzakis; John J. Fung; Thomas E. Starzl

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 746 KB
Volume: 20
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.1840200713

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Model for end-stage liver disease except

Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score–based liver allocation system

✍ Claire Francoz; Jacques Belghiti; Denis Castaing; Olivier Chazouillères; Jean-Ch 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 437 KB 👁 1 views

Model for End-Stage Liver Disease (MELD) score-based allocation systems have been adopted by most countries in Europe and North America. Indeed, the MELD score is a robust marker of early mortality for patients with cirrhosis. Except for extreme values, high pretransplant MELD scores do not signific

Model for end-stage liver disease (MELD)

Model for end-stage liver disease (MELD) exception guidelines: Results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula

✍ Richard B. Freeman Jr.; Robert G. Gish; Ann Harper; Gary L. Davis; John Vierling 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 1 views

Determining need for liver transplantation (LT) can be effectively estimated when the actual liver disease is highly likely to cause death in the near future. However, for many conditions, the liver disease itself does not carry a high risk of short-term mortality, and other factors contribute to de

Diagnosis and management of hemochromato

Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

✍ Bruce R. Bacon; Paul C. Adams; Kris V. Kowdley; Lawrie W. Powell; Anthony S. Tav 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 374 KB 👁 1 views

This guideline has been approved by the American Association for the Study of Liver Diseases (AASLD) and represents the position of the association. ## Preamble These recommendations provide a data-supported approach to establishing guidelines. They are based on the following: (1) a formal review

Liver transplantation for hepatocellular

Liver transplantation for hepatocellular carcinoma: Lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy

✍ Francis Y. Yao; Nathan M. Bass; Nancy L. Ascher; John P. Roberts 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

We examined the impact of the Model for End-Stage Liver Disease (MELD) organ allocation scheme on 44 patients with hepatocellular carcinoma (HCC) awaiting orthotopic liver transplantation (OLT) between February 2002 and January 2003, and compared the outcome with 58 patients listed in the 4 years be

Selection of liver-transplant candidates

Selection of liver-transplant candidates for adult-to-adult living donor liver transplantation as the only surgical option for end-stage liver disease

✍ Noriyo Yamashiki; Yasuhiko Sugawara; Sumihito Tamura; Junichi Kaneko; Kayo Nojir 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

The selection of living donor liver transplantation (LDLT) recipients in regions where deceased donor liver transplantation (DDLT) is rarely performed might be different from that in other centers at which LDLT is an alternative option to DDLT. Records of adult (age > or = 18 yr) patients referred t

Recombinant activated factor VII (rFVIIa

Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: A break from convention in need of controlled trials

✍ Stephen H. Caldwell; Charissa Chang; B. Gail Macik 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 256 KB 👁 1 views

The management of coagulopathy in patients with acute and chronic liver disease has undergone little change in many years despite advances in our understanding of the pathogenesis of this problem. In general, deficiency of clotting factors as a result of poor hepatic synthetic function accounts for